Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nicole A. Favis"'
Autor:
Brittany A. Umer, Ryan S. Noyce, Quinten Kieser, Nicole A. Favis, Mira M. Shenouda, Kim J. Rans, Jackie Middleton, Mary M. Hitt, David H. Evans
Publikováno v:
PLoS ONE, Vol 19, Iss 3 (2024)
Externí odkaz:
https://doaj.org/article/d5115fb703044ebb8c0818da67a442e7
Autor:
Mira M Shenouda, Ryan S Noyce, Stephen Z Lee, Jun Li Wang, Yi-Chan Lin, Nicole A Favis, Megan A Desaulniers, David H Evans
Publikováno v:
PLoS Pathogens, Vol 18, Iss 3, p e1010392 (2022)
Poxvirus genomes consist of a linear duplex DNA that ends in short inverted and complementary hairpin structures. These elements also encode loops and mismatches that likely serve a role in genome packaging and perhaps replication. We constructed mut
Externí odkaz:
https://doaj.org/article/407cb56de70b4475bb13517c4f07fe7a
Autor:
David H. Evans, Mary M. Hitt, Troy A. Baldwin, Megan Desaulniers, Nicole A. Favis, Rees G. Kelly, Mira M. Shenouda, Brian C. Franczak, Ryan S. Noyce, Brittany A. Umer
Vaccinia virus (VACV) is a double-stranded DNA virus that devotes a large portion of its 200 kbp genome to suppressing and manipulating the immune response of its host. Here, we investigated how targeted removal of immunomodulatory genes from the VAC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a706db30eb26ece6707bdc340ea9d3ad
https://doi.org/10.1158/2326-6066.c.6550297.v1
https://doi.org/10.1158/2326-6066.c.6550297.v1
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e84134 (2013)
Myxoma virus (MYXV) is one of many animal viruses that exhibit oncolytic properties in transformed human cells. Compared to orthopoxviruses like vaccinia (VACV), MYXV spreads inefficiently, which could compromise its use in treating tumors and their
Externí odkaz:
https://doaj.org/article/578ad31e6dd24b63a415599f0db5d082
Autor:
Kyle G Potts, Chad R Irwin, Nicole A Favis, Desmond B Pink, Krista M Vincent, John D Lewis, Ronald B Moore, Mary M Hitt, David H Evans
Publikováno v:
EMBO Molecular Medicine, Vol 9, Iss 5, Pp 638-654 (2017)
Abstract Bladder cancer has a recurrence rate of up to 80% and many patients require multiple treatments that often fail, eventually leading to disease progression. In particular, standard of care for high‐grade disease, Bacillus Calmette–Guérin
Externí odkaz:
https://doaj.org/article/7a25d246a5d84cfdbca40ab0fd93b132